{"filings":[{"id":861877,"accession_number":"0001193125-26-257501","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-06-04T20:29:44+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta shareholders approve 2026 equity plans; elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Equity Incentive Plan approved: 63.2M for, 4.4M against; 6,286,841 shares reserved.","2026 Employee Stock Purchase Plan approved: 67.1M for, 0.5M against; 1.5M shares reserved.","Five Class I directors elected: Ingram, Wigzell, Boor, Chambers, Connelly. Connelly had 14.2M against.","Advisory vote on named executive officer compensation passed: 45.2M for, 22.4M against.","Ratification of KPMG as independent auditor approved: 79.9M for, 2.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99309,"accession_number":"0001193125-26-208966","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta Q1 GAAP EPS $2.88 vs loss of $4.60; siRNA pipeline shows early positive data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $330.5M (ELEVIDYS $102.0M, PMO $228.6M); total rev $730.8M (-2% YoY).","GAAP net income $331.0M vs loss of $447.5M; non-GAAP net income $385.4M.","siRNA candidates SRP-1001 (FSHD1) and SRP-1003 (DM1) show dose-dependent exposure and biomarker effects in Phase 1/2.","sNDA submitted to convert AMONDYS 45 and VYONDYS 53 to traditional approval; FY guidance reaffirmed $1.2-1.4B revenue.","ENDEAVOR Cohort 8 dosing underway for non-ambulatory DMD with sirolimus pretreatment; $40M milestone from Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":730803000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115230,"accession_number":"0001193125-26-072064","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta CEO Douglas Ingram to retire by end of 2026; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Douglas Ingram notified retirement by end of 2026 or upon appointment of replacement.","Board has commenced search for successor, considering internal and external candidates.","Ingram will remain CEO until successor is appointed or through 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115229,"accession_number":"0001193125-26-071566","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.","GAAP net loss Q4 $412.2M ($3.93/share) vs Q4 2024 net income $159.0M; full-year GAAP net loss $713.4M.","Ended 2025 with ~$1.0B cash; refinanced $291.4M of 2027 notes to 2030 notes, removing near-term debt.","Japan launch of ELEVIDYS by Chugai in Feb 2026; eligible for $40M milestone. Positive 3-year EMBARK results.","Approval to begin Phase 1 trial of SRP-1005 (siRNA) for Huntington’s disease; Phase 1/2 SRP-1003 for DM1 advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":2198237000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115228,"accession_number":"0001193125-26-010116","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.","ELEVIDYS revenue Q4 $110.4M (impacted by flu and rescheduled infusions), full-year $898.7M.","PMO franchise revenue Q4 $259.2M, full-year $965.6M; described as durable.","CEO reconfirms ELEVIDYS annual sales floor of $500M; more detailed guidance deferred until initiatives evaluated.","Preliminary results unaudited; final Q4/FY 2025 results expected late February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":2198237000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131651,"accession_number":"0001193125-25-326969","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Sarepta exchanges $291.4M of 1.25% notes for 4.875% notes due 2030 plus $31.6M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$291.4M of existing 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Notes due 2030 plus ~$31.6M cash.","New notes issued as additional notes under August 2025 indenture; total 4.875% notes now ~$893.4M outstanding.","Exchange involved holders including entity affiliated with board member Michael Chambers.","Transaction closed December 18, 2025; extends maturity from 2027 to 2030 at higher coupon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131650,"accession_number":"0001193125-25-315032","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Sarepta exchanges $291M of 1.25% notes due 2027 for 4.875% notes due 2030 plus $31.6M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanges $291.4M principal of 1.25% convertibles due 2027 for same principal of 4.875% convertibles due 2030, plus $31.6M in cash.","New 4.875% notes are part of same series as $602M issued Aug 2025; post-exchange total $893.4M outstanding.","Approximately $158.6M of existing 1.25% notes will remain outstanding with unchanged terms.","Placement agent intends to buy ~691,000 SRPT shares in private transactions from exchanging investors at a discount.","Exchange expected to close on or about December 18, 2025, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131649,"accession_number":"0001193125-25-310588","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sarepta grants CEO Ingram $12M equity awards after 8-year gap","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.","Performance awards can pay out 0-200% of target; vesting subject to 3-year service period from Dec 7, 2025.","First equity grant for Ingram since 2017; previously deferred consistent with employment agreement.","Performance condition based on cumulative Incentive EBITDA over two-year period ending Dec 31, 2027.","Up to 269,542 shares at target across four award types (RSUs, units, restricted shares, performance shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131648,"accession_number":"0001193125-25-262591","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).","Net product revenue $370M (PMO $238.5M, ELEVIDYS $131.5M); total revenue $399.4M, down 15% YoY.","GAAP net loss $179.9M ($1.80 per share) vs net income $33.6M ($0.34) in Q3 2024.","Refinanced convertible debt to 2030; disposed Arrowhead equity; positive cash flow in Q3.","ELEVIDYS labeling discussions with FDA nearing conclusion; non-ambulatory indication removal expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1755303000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148217,"accession_number":"0001193125-25-192794","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.","New notes mature Sept 1, 2030; initial conversion price ~$60.00/share (191.5% premium over $20.58 close on Aug 20, 2025).","Concurrent private placement of 1,106,806 shares to J. Wood Capital at $18.07 per share.","New notes bear 4.875% cash interest, payable semiannually; callable from Sept 6, 2028 if stock price ≥ 130% of conversion price.","Holders may convert upon stock price triggers (≥130% of conversion price for 20 of 30 days) or specified corporate events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148216,"accession_number":"0001193125-25-184625","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sarepta exchanges $700M of 1.25% notes due 2027 for new 4.875% notes due 2030, stock, and cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$700M existing 1.25% convertible notes for $602M new 4.875% notes due 2030, $110M stock, and ~$123.3M cash.","New notes conversion price ~$60/share, representing a 191.5% premium over the $20.58 Aug 20 closing price.","Private placement of $20M common stock to J. Wood Capital Advisors at price with floor of $14.41/share.","Up to 835,765 fee shares may be issued to J. Wood Capital Advisors for advisory services.","Exchange expected to close Aug 28, 2025, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148215,"accession_number":"0001193125-25-179819","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta EVP Chief Technical Operations Officer Bilal Arif to depart Sept 16, 2025; severance $576,700","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bilal Arif's employment ends Sept 16, 2025; served as EVP, Chief Technical Operations Officer until Aug 12.","He will serve as Special Advisor to the President for the remainder of his employment.","Severance lump sum of $576,700 plus consulting fee of $400 per hour through Dec 31, 2025.","Outstanding equity awards continue to vest through employment and consulting period.","Departure part of strategic restructuring and pipeline prioritization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148214,"accession_number":"0001193125-25-161516","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places clinical hold on Sarepta's LGMD gene therapy trials; revokes AAVrh74 platform designation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on LGMD trials for SRP-9003, SRP-9004, SRP-6004, and SRP-9005.","Sarepta had paused most LGMD programs on July 16, 2025; SRP-9003 was excepted.","FDA revoked AAVrh74 platform technology designation previously granted on June 2, 2025.","Sarepta plans to discuss accelerated approval pathway for SRP-9003 after clinical hold lifted.","Enrollment and dosing in Phase 3 trial SRP-9003-301 was completed in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148213,"accession_number":"0000950170-25-096257","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.","Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.","FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.","Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.","Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166984,"accession_number":"0000950170-25-083131","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta shareholders approve 4.3M share increase to 2018 equity plan, 0.3M to ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vote approves adding 4,300,000 shares to 2018 Equity Incentive Plan (total now 17,487,596).","Vote approves adding 300,000 shares to 2016 ESPP (total now 1,700,000 shares).","Re-elected directors Barry, Behrens, Mayo, Nicaise with majority support.","Advisory vote on 2024 named executive officer compensation passed (72.1M for, 2.2M against).","Ratified KPMG as independent auditor for FY2025 (80.6M for, 3.9M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184369,"accession_number":"0000950170-25-027717","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.","GAAP net income $159.0M ($1.50 diluted EPS); non-GAAP net income $206.0M ($1.90 EPS).","Full-year 2024 total revenues $1.9B (+53% YoY); GAAP net income $235.2M vs $536M net loss in 2023.","2025 net product revenue guidance $2.9B-$3.1B (70% YoY growth); ELEVIDYS expected to grow 162%.","Closed Arrowhead licensing deal for 4 clinical-stage siRNA programs; established $600M revolving credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1901979000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184368,"accession_number":"0001193125-25-026683","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Sarepta enters $600M senior secured revolving credit facility with JPMorgan as admin agent","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year $600M revolving credit facility closed Feb 13, 2025; variable interest at Adjusted SOFR + 1.125%-1.75% spread based on leverage.","Financial covenants: max secured net leverage ratio 3.5:1.0 (4.0:1.0 holiday for acquisitions); min interest coverage ratio 2.5:1.0.","Facility matures Feb 13, 2030; proceeds for general corporate purposes; secured by substantially all assets of obligors.","Commitment fee on unused portion ranges from 0.20% to 0.35% per annum based on total gross leverage ratio.","Lead arrangers include JPMorgan, Barclays, Citizens, Goldman Sachs, Morgan Stanley, and RBC as co-syndication agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184367,"accession_number":"0001193125-25-005160","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sarepta reports preliminary Q4 2024 net product revenue $638.2M, FY2024 $1.79B, beating guidance by $100M+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.","ELEVIDYS net product revenue Q4 2024 $384.2M (up 112% sequential), FY2024 $820.8M.","RNA-based PMO net product revenue Q4 2024 $254.0M, FY2024 $967.2M, grew YoY.","Cash, cash equivalents, and investments ~$1.5B as of Dec 31, 2024.","Reiterated 2025 full-year net product revenue guidance of $2.9-3.1B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1901979000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200959,"accession_number":"0001193125-24-265627","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","5.02","8.01"],"status":"ready","headline":"Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.","Sarepta purchases 11.9M shares of Arrowhead for $325M in a private placement, with 180-day lock-up and standstill for up to 5 years.","Programs include clinical siRNA candidates for FSHD, DM1, ataxias, IPF, and pre-clinical for Huntington's; Sarepta can select six additional discovery targets.","Arrowhead leads initial development and manufacturing; Sarepta assumes responsibility at transition points and holds global commercialization rights.","EVP Chief General Counsel Ryan Brown resigns effective Nov 26; Cristin Rothfuss named successor as EVP General Counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216974,"accession_number":"0000950170-24-106619","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Sarepta appoints Deirdre Connelly to board, increases board size to 9","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deirdre Connelly appointed as Class I director effective Sept. 12, 2024, term through 2026 annual meeting.","Initial equity grant of $712,500 in value, split equally between RSUs and stock options.","Equity vests in three equal annual installments starting Sept. 12, 2025; annual cash retainer $60,000.","Board amended bylaws to increase maximum director limit from 8 to 9, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236716,"accession_number":"0001193125-24-157458","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta increases incentive plan shares by 500,000; all director nominees elected at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2024 Employment Commencement Incentive Plan, increasing share reserve by 500,000 to 6,185,308 shares.","At June 6 annual meeting, all four Class I director nominees (Douglas Ingram, Hans Wigzell, Kathryn Boor, Michael Chambers) were elected.","Advisory say-on-pay proposal passed with approximately 63.6 million votes for and 9.0 million against.","Stockholders ratified KPMG as independent auditor for 2024; approximately 77.1 million votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254352,"accession_number":"0000950170-24-002822","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sarepta prelim FY2023 net product rev $1.145B; ELEVIDYS $200.4M beats consensus","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2023 total net product revenue of ~$1.145B; RNA PMOs $945.0M (above $925M guidance).","ELEVIDYS net product revenue of $131.3M in Q4 and $200.4M for FY2023, significantly exceeding consensus.","RNA-based PMO net revenue of $234.3M in Q4 and $945.0M for FY2023.","Preliminary cash, equivalents, restricted cash and investments of ~$1.7B as of Dec 31, 2023.","Company to report final Q4/FY2023 results in late February 2024; results subject to adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1243336000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309294,"accession_number":"0000950170-23-029438","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sarepta sets wholesale acquisition cost for ELEVIDYS at $3.2 million","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wholesale acquisition cost (gross price) of gene therapy ELEVIDYS set at $3.2 million.","Indicated for ambulatory pediatric patients aged 4-5 years with DMD gene mutation.","Price disclosed during investor webcast on June 22, 2023.","NASDAQ ticker: SRPT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309293,"accession_number":"0000950170-23-029354","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants accelerated approval for Sarepta's ELEVIDYS gene therapy for Duchenne MD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["First FDA-approved gene therapy for Duchenne muscular dystrophy; for ambulatory patients aged 4-5.","Accelerated approval based on micro-dystrophin expression; confirmatory trial EMBARK reads out late 2023.","Contraindicated in patients with deletions in exon 8 and/or 9 of the DMD gene.","Common adverse reactions include vomiting, nausea, liver enzyme increases, pyrexia, thrombocytopenia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309292,"accession_number":"0000950170-23-027276","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta shareholders reject executive compensation in advisory vote; approve equity plan amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory vote on 2022 named executive officer compensation failed: 52.8M against vs 20.4M for.","Approved Amendment No. 3 to 2018 Equity Incentive Plan, increasing authorized shares by 2.5M to 13.2M.","Approved Amendment No. 2 to ESPP, increasing authorized shares by 300K to 1.4M.","Re-elected directors Barry, Behrens, Mayo, Nicaise as Class II members for two-year terms.","Advisory vote on frequency of future executive compensation votes: one year approved with 73M votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328040,"accession_number":"0001193125-23-058990","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Sarepta exchanges $313.5M of 1.50% convertible notes due 2024 for common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Approximately $313.5M aggregate principal of 1.50% Convertible Senior Notes due 2024 exchanged for shares of common stock.","Exchange consideration: 12.2589 shares per $1,000 principal plus additional shares based on VWAP formula.","Exchange expected to close on March 7, 2023; shares issued in private placement to accredited investors.","Shares will be freely tradable under Rule 144; no cash paid for accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328039,"accession_number":"0000950170-23-000495","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sarepta prelim Q4 revenue $235.5M, FY $843.3M, exceeding guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2022 net product revenue ~$235.5M, up 32% YoY.","Full-year 2022 net product revenue ~$843.3M, up 38% YoY, exceeding guidance of $825-840M.","Year-end cash balance ~$2.0B, down slightly from $2.1B at end of 2021.","Revenues from three RNA-based PMO therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45.","Final Q4/FY results expected in late February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":933013000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345694,"accession_number":"0001193125-22-303900","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sarepta amends bylaws for universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Second Amended and Restated Bylaws, effective December 9, 2022.","Adds advance notice provisions to comply with SEC universal proxy Rule 14a-19.","Stockholders must represent intent to solicit proxies under Rule 14a-19 and provide prompt notice of failures.","Amendments reflect DGCL changes re: adjournment of meetings and elimination of stockholder list requirement.","No successor or substitute nominees allowed after the nomination deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345693,"accession_number":"0001193125-22-275897","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta EVP Technical Ops resigns, Bilal Arif appointed as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William F. Ciambrone to resign as EVP Technical Operations effective Dec 31, 2022.","Ciambrone to consult through Q2 2023 at $500/hour; equity continues vesting.","Board appointed Bilal Arif as Chief Technical Operations Officer effective Dec 31, 2022.","Resignation not due to any disagreement with company operations or policies.","Ciambrone will receive 2022 annual bonus and COBRA coverage through consulting period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362114,"accession_number":"0001193125-22-247130","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Sarepta Therapeutics issues $1.13B in convertible notes, repays $585.5M term loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.13B aggregate principal of 1.25% Convertible Senior Notes due 2027 to initial purchasers including Goldman Sachs and J.P. Morgan.","Sold $20M in notes to Michael A. Chambers Living Trust, an affiliate of board member Michael Chambers.","Prepaid $585.5M term loan from BioPharma Credit, including $7M prepayment premium, terminating the Loan Agreement.","Used proceeds to repurchase $150.6M of existing 1.50% Convertible Senior Notes due 2024.","Entered capped call transactions with five counterparties to reduce potential dilution upon conversion of the notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381623,"accession_number":"0000950170-22-011164","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sarepta shareholders approve 2.5M share increase to 2018 equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved 2018 Plan Amendment, increasing authorized shares by 2.5M to 10,687,596.","All four Class I director nominees elected: Boor, Chambers, Ingram, Wigzell.","Advisory say-on-pay passed with 62,746,933 for (93.2% of votes cast).","KPMG ratified as independent auditor for 2022 with 73,729,807 for.","Equity plan vote: 62,644,364 for, 4,572,292 against, 55,530 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381622,"accession_number":"0001193125-22-112139","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sarepta amends CEO Ingram's stock option; 33% vests immediately; new targets to 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["33.33% (1,099,890 shares) of performance option vested effective April 19, 2022; remainder eligible through June 26, 2025.","Unvested portion triggers at stock prices $105.74, $128.65, $155.37, $186.36, requiring relative CAGR vs Biotech Index.","New one-year holding period on shares acquired upon exercise, except for change in control, death, disability, or certain terminations.","Change-in-control vesting requires minimum $130/share sale price if within 18 months; else next column applies.","Company expects significant non-cash accounting charge for the amendment; to be disclosed in upcoming 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381621,"accession_number":"0000950170-22-005381","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta director Mary Ann Gray to not stand for re-election at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gray informed the Board on March 31, 2022, of her decision to complete her term at the 2022 annual meeting.","Her departure is not due to any disagreement with Sarepta's operations, policies, or practices.","No replacement has been announced for the Board seat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399617,"accession_number":"0000950170-22-000205","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sarepta: $612M FY2021 revenue; SRP-9001 gene therapy shows significant functional improvement in DMD study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2021 revenue $612M, Q4 revenue $178.7M from DMD therapies; cash $2.1B at year-end.","SRP-9001 (delandistrogene moxeparvovec): Part 2 of Study 102 met primary endpoint with NSAA improvement vs external control (p=0.0009).","No new safety signals; no treatment-related SAEs, deaths, or discontinuations in Part 2.","Company reaffirms confidence in EMBARK phase 3 global study, currently dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418603,"accession_number":"0000950170-21-004713","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2021-11-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sarepta appoints Stephen Mayo to board, promotes Rodino-Klapac to R&D head, O'Neill departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen L. Mayo appointed to Sarepta board, effective Nov 16, 2021; receives $712,500 equity grant split between RSUs and options plus $50k annual cash.","Louise Rodino-Klapac promoted to Head of R&D, Chief Scientific Officer; granted 40,000 RSUs vesting 25% annually over 4 years.","Gilmore O'Neill mutually agreed to end employment effective Nov 30, 2021; will serve as consultant through Q1 2022.","Outstanding equity awards issued to O'Neill continue to vest during the consulting period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418602,"accession_number":"0001193125-21-300047","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["1.01","2.02","2.01","8.01","9.01"],"status":"ready","headline":"Sarepta prices $500M common stock offering; preliminary Q3 revenue up 37% to $166.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q3 2021 net product revenue of ~$166.9M, up from $121.4M in Q3 2020.","Cash, cash equivalents and investments were ~$1.6B as of Sept 30, 2021, down from $1.9B at Dec 31, 2020.","Priced public offering of 6,172,840 shares at $81.00/share for gross proceeds of $500M; net proceeds ~$549.1M.","Underwriters granted 30-day option for additional 925,926 shares, exercised in full; closing expected Oct 18, 2021.","Proceeds to fund clinical trials, commercialization, manufacturing, and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436154,"accession_number":"0001564590-21-048961","cik":873303,"company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","form_type":"8-K","filed_at":"2021-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sarepta to initiate pivotal Part B of MOMENTUM study for SRP-5051 in DMD patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive FDA interactions enable early start of Part B of MOMENTUM study for SRP-5051.","Part B expected to serve as pivotal study seeking accelerated approval for exon 51 skipping DMD patients.","Study will enroll 20-40 patients, ages 7-21, both ambulatory and non-ambulatory.","Company anticipates initiating Part B in Q4 2021; protocol submission next week.","SRP-5051 is a next-generation PPMO therapy; prior Part A data suggested efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761011318.1811635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}